AVEO Pharmaceuticals EBIT

AVEO Pharmaceuticals (AVEO) currently reports a EBIT of $-24M as of September 2022. That compares with $-56M in the prior-year period — up 56.3% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore AVEO Pharmaceuticals's EBIT history and peer comparisons.

AVEO Pharmaceuticals's EBIT increased from $-56M to $-24M — a 56.3% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AVEO Pharmaceuticals's EBIT of $-24M is lower than the Healthcare sector average of $22B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

AVEO Pharmaceuticals reported $-24M in EBIT as of September 2022. That compares with $-56M in the prior-year period — up 56.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-24M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for AVEO Pharmaceuticals, and consider following AVEO for alerts when major investors trade the stock.